NL9000237A - Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina - Google Patents

Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina Download PDF

Info

Publication number
NL9000237A
NL9000237A NL9000237A NL9000237A NL9000237A NL 9000237 A NL9000237 A NL 9000237A NL 9000237 A NL9000237 A NL 9000237A NL 9000237 A NL9000237 A NL 9000237A NL 9000237 A NL9000237 A NL 9000237A
Authority
NL
Netherlands
Prior art keywords
oral cavity
aminosalicylic acid
vagina
preparing
potassium
Prior art date
Application number
NL9000237A
Other languages
Dutch (nl)
Original Assignee
Re Novative Drugs For Dermatol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Re Novative Drugs For Dermatol filed Critical Re Novative Drugs For Dermatol
Priority to NL9000237A priority Critical patent/NL9000237A/en
Publication of NL9000237A publication Critical patent/NL9000237A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Abstract

Compsn. is applied to the oral cavity or vagina and contains a cpd. (I) of 5-aminosalicylic acid (ASA) and its derivs. (I) is present in amt. of 0.1-25 wt.% in liq. compsns. or in an amt. of 0.1-500 mg per solid dosage unit. Compsns. pref. contain ASA and have a pH of 3-9.5, adjusted with MHCO3, M2CO3 or MOH (M = Na or K). Compsns. are formulated as mouthwashes, vaginal douches, sprays, tablets, pastilles or chewing gum. Pref. mouth spray comprises 0.1-25g ASA, 1-20g xylitol, 0.1-0.5g peppermint flavour, 5-15g EtOH and H2O to 100ml, under isobutane pressure.

Description

Titel: TOPICALE FARMACEUTISCHE COMPOSITIES VOOR DE MONDHOLTE ENVAGINA.Title: TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE MOUTH CAVITY ENVAGINA.

Samenvatting:Summary:

Een methode ter bereiding van topicale farmaceutische composities voor de mondholte envagina, die 5-aminosalicylzuur of derivaten daarvan bevatten in gewichtsconcentraties van 0.1% tot 25% van de vloeibare composities en/of 0,1 mg tot 500 mg per solidedoseringseenheid.A method of preparing topical pharmaceutical compositions for the oral cavity and vagina, containing 5-aminosalicylic acid or derivatives thereof in weight concentrations of 0.1% to 25% of the liquid compositions and / or 0.1 mg to 500 mg per solid dosage unit.

Het gebruik van deze farmaceutische composities bij ulceratieve en/of erosieve en/ofinflammatoire aandoeningen in de mond-/keelholte en/of vagina en bij aandoeningen inmond-/keelholte en/of vagina, die gekenmerkt worden door een slijmvlies defect en/of doorpijn.The use of these pharmaceutical compositions in ulcerative and / or erosive and / or inflammatory diseases in the mouth / pharynx and / or vagina and in disorders in the mouth / pharynx and / or vagina, which are characterized by a mucous membrane defect and / or pain.

Topicale farmaceutische composities voor de mondholte en/of vagina.Topical pharmaceutical compositions for the oral cavity and / or vagina.

De onderhavige uitvinding heeft betrekking op topicale farmaceutische composities terbehandeling van ulceratieve en/of inflammatoire en/of erosieve aandoeningen in de mond-/keelholte en/of vagina, die al dan niet pijnlijk zijn.The present invention relates to topical pharmaceutical compositions for the treatment of ulcerative and / or inflammatory and / or erosive disorders in the mouth / pharynx and / or vagina, which may or may not be painful.

5-Aminosalicylzuur of te wel 5-amino-2 hydroxybenzoëzuur is een bekende substantie, dievia de orale en rectale route, of via een stoma wordt toegediend ter behandeling vaninflammatoire darmaandoeningen, zoals enteritis regionalis en colitis ulcerosa. Voorts is op 17november 1988 een patentaanvrage gepubliceerd onder nummer EP 0291159-A2, waarinfarmaceutische composities worden beschreven ter behandeling van psoriasis en anderehuidaandoeningen en die 5-aminosalicylzuur bevatten. Hierin wordt niet gesproken vanbehandeling van aandoeningen in de mondholte en/of vagina, noch zijn de farmaceutischecomposities geschikt voor behandeling in de mondholte en/of vagina.5-Aminosalicylic acid, or 5-amino-2-hydroxybenzoic acid, is a known substance administered via the oral and rectal routes or through a stoma to treat inflammatory bowel diseases, such as enteritis regionalis and ulcerative colitis. Furthermore, on November 17, 1988, a patent application was published under number EP 0291159-A2, which describes pharmaceutical compositions for the treatment of psoriasis and other skin disorders and which contain 5-aminosalicylic acid. It does not speak of treatment of conditions in the oral cavity and / or vagina, nor are the pharmaceutical compositions suitable for treatment in the oral cavity and / or vagina.

Vrij frequent komen in de mondholte en/of vagina aandoeningen voor die van inflammatoireaard zijn, bijvoorbeeld stomatitis, gingivitis, erosieve vaginitis, periodontitis, recidiverendestomatitis aphtosa idiopathica, etc, of die een ulceratief aspect hebben, bijvoorbeeld eendruk-ulcus, infectieus ulcus, etc, of die door een tijdelijk slijmvliesdefect zijn gekenmerkt,zoals infecties, traumata, operaties, etc.Quite frequently occur in the oral cavity and / or vagina conditions that are of an inflammatory nature, for example stomatitis, gingivitis, erosive vaginitis, periodontitis, recurrent aphtosa idiopathica, etc., or that have an ulcerative aspect, for example, pressure ulcer, infectious ulcer, etc, or characterized by a temporary mucosal defect, such as infections, trauma, surgery, etc.

De behandeling van dergelijke inflammatoire en/of ulceratieve aandoeningen,slijmvliesdefecten en de pijn bestaat thans uit het toepassen van anti-microbiële middelen inallerlei combinaties en met allerlei hulpstoffen. Voorts worden soms corticosteroïden topicaalgebruikt, ofschoon deze hinderlijke locale bijwerkingen kunnen hebben en ofschoon ookvanuit de mondholte en vagina de resorptie sterk kan zijn. Ook locale anaesthetica, vitaminepreparaten, etc. worden wel gebruikt bij deze aandoeningen.The treatment of such inflammatory and / or ulcerative disorders, mucosal defects and pain currently consists of the use of anti-microbial agents in all kinds of combinations and with various auxiliary substances. Furthermore, corticosteroids are sometimes used topically, although these can have bothersome local side effects and although absorption from the oral cavity and vagina can also be strong. Local anesthetics, vitamin preparations, etc. are also used in these conditions.

Recidiverende stomatitis aphtosa idiopathica is bijvoorbeeld zo een aandoening, waarbij ophet mondslijmvlies en/of op de tong in korte tijd pijnlijke vesicels ontstaan, die overgaan inerosies en uiteindelijk zonder litteken genezen binnen enkele weken. Een volgende uitbraakvan de ziekte kan weken tot jaren later zijn. De oorzaak van deze aandoening is niet bekend,zodat slechts een symptomatische behandeling, zoals oraal acetylsalicylzuur en behandelingenzoals met het etsende negatol of met corticosteroïden worden voorgeschreven.For example, recurrent aphtosa idiopathica stomatitis is a condition in which painful vesicles develop on the oral mucosa and / or on the tongue in a short time, which pass into erosions and eventually heal without a scar within a few weeks. A subsequent outbreak of the disease may be weeks to years later. The cause of this condition is unknown, so only symptomatic treatment, such as oral acetylsalicylic acid and treatments such as the etching negatol or corticosteroids, are prescribed.

Daar vele van de bovengenoemde aandoeningen zeer hinderlijk en pijnlijk kunnen zijn en erthans geen curatieve therapie voor handen is, is het wenselijk dat er een locaal werkend,veilig en bij voorkeur pijnstillend geneesmiddel komt, dat de genezing van dezeaandoeningen bespoedigt en bijvoorbeeld in het geval aphten wellicht de remissietijdverlengt.Since many of the above conditions can be very bothersome and painful and at least curative therapy is not available, it is desirable to have a locally effective, safe and preferably analgesic medicine that accelerates the healing of these conditions and, for example, remedies them may extend the remission time.

Verrassenderwijs is nu vastgesteld dat een mondspoeling, die 5-aminosalicylzuur bevat in eengewichtspercentage van 0,1% tot 25%, in het bijzonder tussen 1% en 10%, bij voorkeur tussen2% en 5%, de geneestijd van recidiverende stomatitis aphtosa idiopathica sterk bekort en datde typische pijn bij aphten sterk afneemt.Surprisingly, it has now been found that a mouthwash containing 5-aminosalicylic acid in a weight percentage of 0.1% to 25%, in particular between 1% and 10%, preferably between 2% and 5%, strongly heals the time of recurrent aphtosa idiopathica stomatitis. shortened, and that the typical pain when applying is greatly reduced.

Voorts vermindert 5-aminosalicylzuur de pijn bij en bespoedigt het de genezing vanstomatitis, erosieve vaginitis, gingivitis, periodontitis en druk-ulcera als gevolg van niet-passende gebitsprothesen, etc.Furthermore, 5-aminosalicylic acid reduces pain and accelerates the healing of stomatitis, erosive vaginitis, gingivitis, periodontitis and pressure ulcers due to improper dentures, etc.

De volgende voorbeelden lichten de uitvinding toe zonder deze op enigerlei wijze tebeperken.The following examples illustrate the invention without limiting it in any way.

Voorbeeld 1Example 1

Mondspoeling/vaginaal spoeling van de volgende samenstelling: 5-Aminosalicylzuur 0,1 - 10 gMouth rinse / vaginal rinse of the following composition: 5-Aminosalicylic acid 0.1 - 10 g

Na2P04 12H20 240 mgNa2 PO4 12H20 240 mg

Na2P04 2H20 940 mgNa 2 PO 4 2H 2 O 940 mg

Natriumdisulfiet 100 mgSodium disulfite 100 mg

Polyvinylpyrrolidon 2,5 gPolyvinylpyrrolidone 2.5 g

Saccharide natrium 10 mgSaccharide sodium 10 mg

Citroenzuur 300 mgCitric acid 300 mg

Solutio MoB FNA 1 mlSolutio MoB FNA 1 ml

Aqua purificata tot 100 mlAqua purificata up to 100 ml

Variaties in type en hoeveelheid buffer en/of conserveermiddelen en/of verdikkingsmiddelenen/of smaakmiddelen zijn hierbij mogelijk.Variations in type and amount of buffer and / or preservatives and / or thickeners and / or flavors are possible here.

Voorbeeld 2Example 2

Mondspray vanuit een onder isobutaandruk staand vat: 5-Aminosalicylzuur 0,1 - 25 gMouth spray from an isobutane-pressured vessel: 5-Aminosalicylic acid 0.1 - 25 g

Xylitol 1 - 20 gXylitol 1 - 20 g

Pepermunt 0,1 - 0,5 gPeppermint 0.1 - 0.5 g

Ethanol 5 - 15 gEthanol 5-15 g

Gedestilleerd water tot 100 mlDistilled water to 100 ml

Voorbeeld 3Example 3

Zuigpastille (voor de bereiding van 100 g pastille-basis):5-Aminosalicylzuur 0,1 - 50 gSuction pastille (for the preparation of 100 g pastille base): 5-Aminosalicylic acid 0.1 - 50 g

Natrium-bicarbonaat 0,1 - 5 gSodium bicarbonate 0.1-5 g

Suiker 40 - 80 gSugar 40 - 80 g

Maïsstroop 1 - 25 gCorn syrup 1 - 25 g

Smaakstof 0,1 - 1,0 gFlavor 0.1 - 1.0 g

Magnesiumstearaat 1 - 5 gMagnesium stearate 1 - 5 g

Water 0,05 - 0,5 gWater 0.05 - 0.5 g

Voorbeeld 4Example 4

Zuigpastille (voor de bereiding van 100 g pastille-basis):5-Aminosalicylzuur 0,1 - 50 gSuction pastille (for the preparation of 100 g pastille base): 5-Aminosalicylic acid 0.1 - 50 g

Natrium-bicarbonaat 0,1 - 5 gSodium bicarbonate 0.1-5 g

Arabische gom 25 - 40 gGum arabic 25 - 40 g

Xylitol 25 - 65 gXylitol 25 - 65 g

Pepermunt 0,1 - 1,0 gPeppermint 0.1 - 1.0 g

Voorbeeld 5Example 5

Pastille (voor de bereiding van 100 g pastille-basis):5-Aminosalicylzuur 0,1 - 50 gPastille (for the preparation of 100 g pastille base): 5-Aminosalicylic acid 0.1 - 50 g

Natrium-bicarbonaat 0,1 - 5 gSodium bicarbonate 0.1-5 g

Sorbitol poeder 48,5 - 98,5 gSorbitol powder 48.5 - 98.5 g

Pepermunt 0,1 - 1,0 gPeppermint 0.1 - 1.0 g

Magnesium stearaat 0,75 - 1,25 gMagnesium stearate 0.75 - 1.25 g

Voorbeeld 6Example 6

Kauwgom (voor de bereiding van 100 g kauwgom-basis):5-Aminosalicylzuur 0,1 - 30 gChewing gum (for the preparation of 100 g of chewing gum base): 5-Aminosalicylic acid 0.1 - 30 g

Kauwgombasis 24 - 38 gChewing gum base 24 - 38 g

Xylitol 35 - 60 gXylitol 35 - 60 g

Maïsstroop 10 - 20 gCorn syrup 10 - 20 g

Smaakstof 0,1 - 1,0 gFlavor 0.1 - 1.0 g

Gedestilleerd water 1,0 - 5,0 gDistilled water 1.0-5.0 g

Claims (16)

1. Een methode ter bereiding van topicale farmaceutische composities voor de mondholteen/of vagina met het kenmerk, dat deze 5-aminosalicylzuur of derivaten daarvanbevatten in gewichtsconcentraties van 0,1% tot 25% van de vloeibare composities en/of0,1 mg tot 500 mg per solide doseringseenheid.A method of preparing topical pharmaceutical compositions for the oral cavity and / or vagina, characterized in that it contains 5-aminosalicylic acid or derivatives thereof in weight concentrations of 0.1% to 25% of the liquid compositions and / or 0.1 mg to 500 mg per solid dosage unit. 2. Een methode ter bereiding van een farmaceutische compositie als beschreven in claim1 met het kenmerk, dat de 5-aminosalicylzuur wordt toegediend in de vorm van eenmondspoeling.A method of preparing a pharmaceutical composition as described in claim 1, characterized in that the 5-aminosalicylic acid is administered in the form of a mouthwash. 3. Een methode ter bereiding van een farmaceutische compositie als beschreven in claim1 met het kenmerk, dat de 5-aminosalicylzuur wordt toegediend in de vorm van eenvaginaalspoeling.A method of preparing a pharmaceutical composition as described in claim 1, characterized in that the 5-aminosalicylic acid is administered in the form of a vaginal wash. 4. Een methode als beschreven in claim 2 en 3 met het kenmerk, dat de zuurgraad hogeris dan pH=3,0 en lager dan pH=9,5.A method as described in claims 2 and 3, characterized in that the acidity is higher than pH = 3.0 and lower than pH = 9.5. 5. Een methode als beschreven in claim 4 met het kenmerk, dat natrium-bicarbonaat, ofnatrium-carbonaat, of natronloog, of kalium-bicarbonaat, of kalium-carbonaat, ofkaliloog is toegevoegd, of een mengsel van genoemde substanties, of van anderebasische zouten.A method as described in claim 4, characterized in that sodium bicarbonate, or sodium carbonate, or caustic soda, or potassium bicarbonate, or potassium carbonate, or potassium hydroxide, or a mixture of said substances, or other basic salts . 6. Een methode ter bereiding van een farmaceutische compositie als beschreven in claim1 met het kenmerk, dat de 5-aminosalicylzuur wordt toegediend als een spray.A method of preparing a pharmaceutical composition as described in claim 1, characterized in that the 5-aminosalicylic acid is administered as a spray. 7. Een methode als beschreven in claim 6 met het kenmerk, dat de zuurgraad hoger isdan pH=3,0 en lager dan pH=9,5.A method as described in claim 6, characterized in that the acidity is greater than pH = 3.0 and less than pH = 9.5. 8. Een methode als beschreven in claim 7 met het kenmerk, dat natrium-bicarbonaat, ofnatrium-carbonaat, of natronloog, of kalium-bicarbonaat, of kalium-carbonaat, ofkaliloog is toegevoegd, of een mengsel van genoemde substanties, of andere basischezouten.A method as described in claim 7, characterized in that sodium bicarbonate, or sodium carbonate, or caustic soda, or potassium bicarbonate, or potassium carbonate, or potassium hydroxide, is added, or a mixture of said substances, or other basic salts. 9. Een methode ter bereiding van een farmaceutische compositie als beschreven in claim1 met het kenmerk, dat de 5-aminosalicylzuur wordt toegediend als een tablet, of alszuigtablet, of als kauwtablet, of als pastille, of als zuigpastille, of een andere solidefarmaceutische compositie voor topicale behandeling van vaagina en mondholte.A method of preparing a pharmaceutical composition as described in claim 1, characterized in that the 5-aminosalicylic acid is administered as a tablet, or as a lozenge, or as a chewable tablet, or as a lozenge, or as a lozenge, or another solid pharmaceutical composition for topical treatment of vagina and oral cavity. 10. Een methode als beschreven in claim 9 met het kenmerk, dat natrium-bicarbonaat, ofnatrium-carbonaat, of kalium-bicarbonaat, of kalium-carbonaat, is toegevoegd, of eenmengsel van genoemde substanties, of andere basische zouten.A method as described in claim 9, characterized in that sodium bicarbonate, or sodium carbonate, or potassium bicarbonate, or potassium carbonate, is added, or a mixture of said substances, or other basic salts. 11. Een methode ter bereiding van een farmaceutische compositie als beschreven in claim1 met het kenmerk, dat de 5-aminosalicylzuur wordt toegediend in de vorm van eenkauwgom.A method of preparing a pharmaceutical composition as described in claim 1, characterized in that the 5-aminosalicylic acid is administered in the form of chewing gum. 12. Een methode als beschreven in claim 11 met het kenmerk, dat natrium-bicarbonaat, ofnatrium-carbonaat, of kalium-bicarbonaat, of kalium-carbonaat, of salmiak, of eenmengsel van genoemde zouten, of andere basische zouten worden toegevoegd.A method as described in claim 11, characterized in that sodium bicarbonate, or sodium carbonate, or potassium bicarbonate, or potassium carbonate, or salmiac, or a mixture of said salts, or other basic salts are added. 13. Een methode als beschreven in claims 2 t/m 12 met het kenmerk, dat sorbitol ofxylitol of een mengsel van beide suikers en/of andere suikers tesamen met een aroma,bijvoorbeeld pepermunt, is/zijn toegevoegd.A method as described in claims 2 to 12, characterized in that sorbitol or xylitol or a mixture of both sugars and / or other sugars is / are added together with an aroma, for example peppermint. 14. Een methode als beschreven in claim 1 met het kenmerk, dat andere, niet in claims 2t/m 12 beschreven, farmaceutische composities voor de mondholte en vagina wordenbereid en toegepast.A method as described in claim 1, characterized in that other pharmaceutical compositions for oral cavity and vagina, not described in claims 2 to 12, are prepared and used. 15. Het gebruik van de farmaceutische composities beschreven in claims 1 t/m 14 voor detopicale behandeling van ulceratieve en/of erosieve en/of inflammatoire aandoeningenvan het mond-/keelslijmvlies, tandvlees, tong, gebitselementen en andere structurendie aan de mondholte grenzen en van het vaginale slijmvlies.15. The use of the pharmaceutical compositions described in claims 1 to 14 for the topical treatment of ulcerative and / or erosive and / or inflammatory diseases of the mouth / throat mucosa, gums, tongue, teeth and other structures adjacent to the oral cavity and of the vaginal mucosa. 16. Het gebruik van de farmaceutische composities beschreven in claims 1 t/m 14 voor hetbestrijden van pijn bij kauwen, eten, slikken, etc. als gevolg van laesies in mondholte,bijvoorbeeld aphten, ulceraties, inflammatoire aandoeningen, traumata, post¬operatieve pijn, slijmvliesdefecten bij infectieuze aandoeningen, etc.16. The use of the pharmaceutical compositions described in claims 1 to 14 for combating pain in chewing, eating, swallowing, etc., due to lesions in the oral cavity, for example, ulcerations, ulcerations, inflammatory conditions, trauma, post-operative pain , mucous membrane defects in infectious diseases, etc.
NL9000237A 1990-01-31 1990-01-31 Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina NL9000237A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL9000237A NL9000237A (en) 1990-01-31 1990-01-31 Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9000237A NL9000237A (en) 1990-01-31 1990-01-31 Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina
NL9000237 1990-01-31

Publications (1)

Publication Number Publication Date
NL9000237A true NL9000237A (en) 1991-08-16

Family

ID=19856515

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9000237A NL9000237A (en) 1990-01-31 1990-01-31 Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina

Country Status (1)

Country Link
NL (1) NL9000237A (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627915A1 (en) * 1992-12-04 1994-12-14 Mayor Pharmaceuticals Laboratories,Inc. Sprayable analgesic composition and method of use
WO1998006387A2 (en) * 1996-08-13 1998-02-19 Tillotts Pharma Ag Oral composition comprising 5-aminosalicylic acid
EP1063885A1 (en) * 1998-03-24 2001-01-03 Alonzo H. Jones Xylitol compositions for treating upper respiratory conditions
WO2001041753A2 (en) * 1999-12-07 2001-06-14 Rutgers, The State University Of New Jersey Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
US6613807B2 (en) 2000-07-27 2003-09-02 Rutgers, The State University Of New Jersey Therapeutic polyanhydride compounds for drug delivery
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US6689350B2 (en) 2000-07-27 2004-02-10 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
EP1444976A1 (en) * 2003-02-10 2004-08-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US8088405B2 (en) 1999-12-07 2012-01-03 Rutgers, The State University of New Jersery Therapeutic compositions and methods
ES2387487A1 (en) * 2012-07-12 2012-09-24 Nuria LLONCH BERGÉS Utilization of xylitol and compositions thereof (Machine-translation by Google Translate, not legally binding)
US8741317B2 (en) 2010-08-19 2014-06-03 Rutgers, The State University Of New Jersey Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery
US9108070B2 (en) 2006-09-13 2015-08-18 Polymerix Corporation Active agents and their oligomers and polymers
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
US9782432B2 (en) 2012-10-25 2017-10-10 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
US10543162B2 (en) 2015-04-10 2020-01-28 Rutgers, The State University Of New Jersey Kojic acid polymers

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627915A1 (en) * 1992-12-04 1994-12-14 Mayor Pharmaceuticals Laboratories,Inc. Sprayable analgesic composition and method of use
EP0627915A4 (en) * 1992-12-04 1996-02-07 Mayor Pharma Lab Inc Sprayable analgesic composition and method of use.
WO1998006387A2 (en) * 1996-08-13 1998-02-19 Tillotts Pharma Ag Oral composition comprising 5-aminosalicylic acid
WO1998006387A3 (en) * 1996-08-13 1998-03-19 Tillotts Pharma Ag Oral composition comprising 5-aminosalicylic acid
US6217897B1 (en) * 1996-08-13 2001-04-17 Tillotts Pharma Ag Oral mucosal composition comprising 5-aminosalicylic acid
US8017714B2 (en) 1997-09-10 2011-09-13 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US7534852B2 (en) 1997-09-10 2009-05-19 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
EP1063885A1 (en) * 1998-03-24 2001-01-03 Alonzo H. Jones Xylitol compositions for treating upper respiratory conditions
EP1063885A4 (en) * 1998-03-24 2002-09-18 Alonzo H Jones Xylitol compositions for treating upper respiratory conditions
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
WO2001041753A3 (en) * 1999-12-07 2002-09-12 Univ Rutgers Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
WO2001041753A2 (en) * 1999-12-07 2001-06-14 Rutgers, The State University Of New Jersey Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
US8088405B2 (en) 1999-12-07 2012-01-03 Rutgers, The State University of New Jersery Therapeutic compositions and methods
US6613807B2 (en) 2000-07-27 2003-09-02 Rutgers, The State University Of New Jersey Therapeutic polyanhydride compounds for drug delivery
US6689350B2 (en) 2000-07-27 2004-02-10 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
US8241668B2 (en) 2000-07-27 2012-08-14 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
US8221790B2 (en) 2000-07-27 2012-07-17 Rutgers, The State University Of New Jersey Therapeutic polyesters and polyamides
EP1444976A1 (en) * 2003-02-10 2004-08-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US9108070B2 (en) 2006-09-13 2015-08-18 Polymerix Corporation Active agents and their oligomers and polymers
US10092578B2 (en) 2006-09-13 2018-10-09 Polymerix Corporation Active agents and their oligomers and polymers
US8741317B2 (en) 2010-08-19 2014-06-03 Rutgers, The State University Of New Jersey Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery
ES2387487A1 (en) * 2012-07-12 2012-09-24 Nuria LLONCH BERGÉS Utilization of xylitol and compositions thereof (Machine-translation by Google Translate, not legally binding)
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
US9782432B2 (en) 2012-10-25 2017-10-10 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
US10543162B2 (en) 2015-04-10 2020-01-28 Rutgers, The State University Of New Jersey Kojic acid polymers

Similar Documents

Publication Publication Date Title
NL9000237A (en) Topical medicaments contg. 5-amino-salicylic acid - for treating inflammatory, erosive or ulcerative disorders of oral cavity or vagina
JP4111916B2 (en) Composition for alleviating xerostomia and treating related diseases
RU2448711C2 (en) Oral care compositions containing combinations of antibacterial agents and agents changing carrier body reaction
ES2309077T3 (en) ORAL COMPOSITIONS THAT INCLUDE ANTIMICROBIAL AGENTS FOR THE PREVENTION OF SYSTEMIC DISEASES.
US5977087A (en) Topical preparation for treatment of aphthous ulcers and other lesions
CZ289643B6 (en) Flurbiprofen lozenge for the treatment of sore throat
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
US4970236A (en) Mouth-soluble pharmaceutical compositions containing acetyl-cysteine
JP2005533047A (en) Compositions and methods for prevention and treatment of after ulcers and herpes simplex lesions
US4457909A (en) Oral rinse formulation and method of treating mouth and throat irritations therewith
US5658554A (en) Mouth moistener for the relief of dry mouth condition
AU2003232480B2 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
IL31858A (en) Concentrated liquid antacid compositions
KR20000022204A (en) Preventives/remedies for stomatitis
DE19949575A1 (en) Fluoride and flavonoid combination, e.g. in chewing gum and toothpaste, for the prevention of caries and the treatment of dental disorders
IE61381B1 (en) Topically applied gold organic complex
JPH039883B2 (en)
RU2813879C1 (en) Anti-inflammatory composition (versions) for local application in oral cavity and upper respiratory tract
JPH10298045A (en) Composition for oral cavity
ES2235443T3 (en) TOPIC PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS, WHICH ARE OF BORNEOL AND BISMUTO SUBGALATE.
JPS59227812A (en) Composition for oral cavity application
EP3236951B1 (en) Oral dissolvable pharmaceutical dosage form for the treatment of oral diseases
EP1380294A1 (en) Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like
JP2015178462A (en) Oral rinsing agent of ibuprofen
RU2380081C2 (en) Composition for treatment and prevention of oral diseases

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BV The patent application has lapsed